Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors

@article{Esposito2015SyntheticLT,
  title={Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors},
  author={M. Esposito and Lu Zhao and T. Fung and J. Rane and Amanda J. Wilson and Nadine Martin and J. Gil and A. Y. Leung and A. Ashworth and Chi Wai Eric So},
  journal={Nature Medicine},
  year={2015},
  volume={21},
  pages={1481-1490}
}
Acute myeloid leukemia (AML) is mostly driven by oncogenic transcription factors, which have been classically viewed as intractable targets using small-molecule inhibitor approaches. Here we demonstrate that AML driven by repressive transcription factors, including AML1-ETO (encoded by the fusion oncogene RUNX1-RUNX1T1) and PML-RARα fusion oncoproteins (encoded by PML-RARA) are extremely sensitive to poly (ADP-ribose) polymerase (PARP) inhibition, in part owing to their suppressed expression of… Expand
Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders.
TLDR
The rationale for using PARPi in AML subtypes characterized by a specific genetic background is discussed, the preclinical and clinical evidence reported so far on their activity when used as single agents or in combination with classical cytotoxic chemotherapy or with agents targeting AML-associated mutated proteins are summarized. Expand
Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.
TLDR
The results suggest a novel therapeutic approach for treating refractory leukemia, particularly the TCF3-HLF-positive subtype, and the PARP inhibitor olaparib was effective in an in vivo xenograft model. Expand
Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells
TLDR
GEMA-guided targeting of PARP1 resulted in dual cellular synthetic lethality in quiescent and proliferating immature leukemia cells, and is thus a potential approach to eradicate leukemia stem and progenitor cells that are responsible for initiation and manifestation of the disease. Expand
GADD45g acts as a novel tumor suppressor and its activation confers new combination regimens for the treatment of AML.
TLDR
The findings uncover hitherto unreported evidence for the selective anti-leukemia role of GADD45g and provide novel strategies for the treatment of FLT3-ITD+ and MLL-AF9+ AML. Expand
Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma
TLDR
It is proposed that combined blockade of ATR and PARP is an effective strategy for GBM, even for low-Myc GSCs that do not respond to PARPi alone, and potentially other PARPi-refractory tumors. Expand
MiR-181a enhances drug sensitivity of mixed lineage leukemia-rearranged acute myeloid leukemia by increasing poly(ADP-ribose) polymerase1 acetylation
TLDR
MiR-181a overexpression enhanced total protein acetylation in THP-1 cells, which harbor MLL-AF9 fusion gene, and protein Mass Spectrum identified poly(ADP-ribose) polymerase 1 (PARP1) was a major downstream target. Expand
Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor
TLDR
A second-generation VCP inhibitor was developed, CB-5339, which effectively treated AML and prolonged survival in syngeneic and patient-derived xenograft mouse models when used alone or when combined with anthracycline and cytarabine, and established that AML was the most responsive disease to chemical inhibition of VCP across a panel of 16 cancer types. Expand
Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
TLDR
It is postulate that FLT3i-induced deficiencies in DSB repair pathways sensitizeFLT3(ITD)-positive AML cells to synthetic lethality triggered by PARP1i's. Expand
PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias.
TLDR
Evidence of modest clinical efficacy and tolerability in combinatorial regimens support the further development of PARP inhibition as a novel therapeutic strategy for AML, particularly in select molecular subsets (MLL rearranged, FLT3 and IDH1 mutant disease). Expand
TGFβR-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment.
TLDR
It is reported that the bone marrow microenvironment (BMM) facilitates DSB repair activity in leukemia cells to protect them against PARPi-mediated synthetic lethality and may lead to the therapeutic application of the TGFβR inhibitor in patients receiving PARPis. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 77 REFERENCES
Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair.
TLDR
It is proposed that expansion of the stem cell compartment and induction of a mutator phenotype are relevant features underlying the leukemic potential of AML-associated fusion proteins. Expand
Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma.
HOXA genes encode critical transcriptional regulators of embryonic development that have been implicated in cancer. In this study, we documented functional relevance and mechanism of activation ofExpand
HOXA9 is required for survival in human MLL-rearranged acute leukemias.
Leukemias that harbor translocations involving the mixed lineage leukemia gene (MLL) possess unique biologic characteristics and often have an unfavorable prognosis. Gene expression analysesExpand
Mixed lineage leukemia protein in normal and leukemic stem cells
  • B. Yip, C. So
  • Biology, Medicine
  • Experimental biology and medicine
  • 2013
TLDR
Key features of both wild-type and re-arranged MLL proteins are reviewed with particular focuses on MLL-PTD and MLL amplification for their roles in normal and malignant hematopoiesis. Expand
DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance
TLDR
The current review summarizes the DDR pathways in the context of AML and describes how aberrant DNA damage response can affect AML pathogenesis, disease progression, and resistance to standard chemotherapy, and how defects in DDR pathways may provide a new avenue for personalized therapeutic strategies in AML. Expand
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
TLDR
It is proposed that, in the absence of PARP1, spontaneous single-strand breaks collapse replication forks and trigger homologous recombination for repair and exploited in order to kill BRCA2-deficient tumours by PARP inhibition alone. Expand
DNA damage response and inflammatory signaling limit the MLL-ENL-induced leukemogenesis in vivo.
TLDR
The results indicate that DDR is a rate-limiting event for acquisition of stem cell-like properties in MLL-ENL-ERtm-mediated transformation, as experimental inhibition of the barrier accelerated the transition to immature cell states and acute leukemia development. Expand
Promyelocytic leukemia nuclear bodies support a late step in DNA double‐strand break repair by homologous recombination
TLDR
Findings indicate that early steps in HRR, including recognition of DNA double‐strand breaks, initial processing of ends, and assembly of single‐stranded DNA/RAD51 nucleoprotein filaments, do not depend upon PML‐NB, and the HRR deficit inPML‐depleted cells thus reflects inhibition of later steps in the repair pathway. Expand
Functional Connection between Rad51 and PML in Homology-Directed Repair
TLDR
It is shown that PML knockdown inhibits viral replication in vivo, thus indicating a positive role of PML early in infection, and a novel functional connection between PML and the homologous recombination-mediated repair machinery, which might contribute to PML tumor suppressor activity. Expand
Myeloid leukemias have increased activity of the nonhomologous end-joining pathway and concomitant DNA misrepair that is dependent on the Ku70/86 heterodimer.
TLDR
The findings suggest that an overactive NHEJ system and, specifically, aberrant Ku70/86 activity is a candidate mechanism for chromosomal instability in myeloid leukemias. Expand
...
1
2
3
4
5
...